Table I.
Patient clinical and therapeutic data.
| Pt. | Age (y) | Metastatic area | Induction chemotherapy | Treatment area (KORTUC II field) | FDG accumulation | Tumor size (mm) | Therapeutic effect |
|---|---|---|---|---|---|---|---|
| 1 | 63 | Bone, lung and lymph node | PTX × 15 | Left breast | 5.6→Da | 14→10 | PR |
| 2 | 57 | Lymph node and skin | FEC × 8 | Left breast | 7.7→Da | 28→Da | CRb |
| 3 | 65 | Bone, lung and lymph node | EC × 6 | Left breast | 11.2→Da | 15→3 | CRb |
| 4 | 58 | Lymph node and skin | EC × 3 | Right breast | 8.6→Da | 28→14 | CRb |
| 5 | 55 | Lung | EC × 3 | Left breast | 6.2→2.2 | 28→22 | PR |
| 6 | 36 | Lymph node | FEC × 4 and PTX × 12 | Right breast | No data→2.5 | No data→Da | CRb |
| 7 | 51 | Bone | EC × 9 and TXT × 6 | Left breast | 5.1→Da | 23→Da | CRb |
a
D was defined as the disappearance of cancer shadows following CT examination.
b
The criteria for CR was the dissipation of FDG accumulation as determined by PET-CT or the tumor lesion as determined by CT. RT field, radiation therapy field; CR, complete response; PR, partial response; D, disappearance; X, x-ray; E, electron beam; PTX, paclitaxel; EC, epirubicin and cyclophosphamide; FEC, fluorouracil and epirubicin and cyclophosphamide; TXT, docetaxel hydrate; Pt, patient; KORTUC II, Kochi Oxydol Radiation Therapy for Unresectable Carcinomas II; FDG, fluorodeoxyglucose; PET-CT, positron emission tomography-computed tomography.